Subcutaneous immunoglobulin market to reach $8.8 billion by 2024
The global subcutaneous immunoglobulin market is likely to present an opportunity-filled landscape for new players in the coming years, while steady expansion efforts are likely to help existing market players consolidate their position in this sector.
Key companies in the global subcutaneous immunoglobulin market include Spain’s Grifols (GRLS: MC), CSL Behring, Shire (LSE: SHP), Germany’s Biotest (BIO: Xetra), Italy’s Kedrion, Switzerland’s Octapharma, Baxalta (part of Shire), and Talecris Biotherapeutics (now part of Grifols).
According to Transparency Market Research (TMR), the global Subcutaneous Immunoglobulin Market is expected to exhibit a robust 14% compound annual growth rate (CAGR) between 2016 and 2024. The market was valued at $2.7 billion in 2015 and is expected to rise to a valuation of $8.8 billion by 2024.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
More on this story...
Today's issue
Company Spotlight
More Features in Pharmaceutical
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze